Teva Oncology announced the launch of a new single-use pre-filled syringe for self-administration for Granix (tbo-filgrastim) solution for injection.

Granix is a granulocyte colony stimulating factor indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

RELATED: New Triferic Replaces Iron Losses, Maintains Hemoglobin in Hemodialysis Patients

The new Granix self-administration syringes will be available as 300mcg/0.5mL and 480mcg/0.8mL strengths in 1- and 5-count packages. The syringes with safety needle guards will continue to be available for use by healthcare professionals.

For more information call (866) 832-8537 or visit